Last update Jan. 7, 2018


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Main component (>45%) of Oxerutins that are derived from a naturally occurring Bioflavonoid, Rutin.

Flavonoids are phenolic compounds naturally occurring that are abundantly present in plants and seaweed.

We take it from fruits, vegetables, tea and red wine (as a few examples)

Most important types are: anthocyanins, chalcons, flavonols, flavones, flavonoids and tannins. No risk for toxic nor side-effects in humans have been found.

They appear naturally in the breast milk in amounts related to mother's diet.

Attributed anti-oxidant activity and other properties that have not been fully shown yet (Martinez 2016, Morling 2015, Cohen 2012), as amelioration of capillary vessel function which is a reason to be used for treatment of venous insufficiency (varicose veins) and prevention of arteriosclerosis.


We do not have alternatives for Troxerutin since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Troxerutin is also known as

Troxerutin in other languages or writings:


Main tradenames from several countries containing Troxerutin in its composition:


Variable Value Unit
Oral Bioavail. 60 - 98 %
Molecular weight 743 daltons
Protein Binding 30 %
Tmax 1 - 9 hours
T1/2 10 - 25 hours


  1. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Abstract
  2. Morling JR, Yeoh SE, Kolbach DN. Rutosides for treatment of post-thrombotic syndrome. Cochrane Database Syst Rev. 2015 Abstract
  3. Song BJ, Jouni ZE, Ferruzzi MG. Assessment of phytochemical content in human milk during different stages of lactation. Nutrition. 2013 Abstract Full text (link to original source) Full text (in our servers)
  4. Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest. 2012 Abstract
  5. Troxerutina. Ficha técnica. 2011 Full text (in our servers)
  6. Kienzler JL, Sallin D, Schifflers MH, Ghika A. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers. Eur J Clin Pharmacol. 2002 Abstract
  7. Dittrich P, Ostrowski J, Beubler E, Schraven E, Kukovetz W. [HPLC determination of troxerutin in plasma and urine following oral administration in man]. Arzneimittelforschung. 1985 Abstract
  8. Krajnovic P. [The influence of the combination of coumarin and troxerutin on infantile blood parameter in lactation period. Short communication (author's transl)]. Arzneimittelforschung. 1977 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM